LEO selects Veeva CRM to support its rapidly growing New Markets Europe region

NewsGuard 100/100 Score

LEO Pharma, a leading global pharmaceutical company specialising in dermatology and critical care, has selected Veeva CRM to support its rapidly growing New Markets Europe region. LEO has started the deployment of Veeva CRM to its users in countries such as Hungary, Czech Republic, Slovakia, Poland, Romania, and Italy.

"We were looking for an innovative CRM solution that was aligned and harmonised across countries and could be deployed quickly. It became clear early on that Veeva had the most comprehensive and agile pharma CRM solution and offered the shortest timeframe to implementation," commented Rene J0rgensen, global manager CRM and e-tools for LEO Pharma A/S.

General Manager for LEO Hungary, Jozsef Vincze, added "Given our rapid growth and expansion into new markets and regions, we were searching for a flexible and easy to use system that would support our customer-focused and performance-driven strategies. Veeva CRM has everything we need."

Over the past four years, Veeva Systems has quickly become a leading global provider of Pharma CRM solutions. Because of its cloud-based platform, Veeva CRM requires no hardware or software to purchase, scale, or maintain. In addition, all Veeva customers benefit from free, automatic upgrades so users are always on the latest version of the software, aiding in regulatory compliance while enhancing overall system performance.

"We are delighted that LEO has selected Veeva as its partner for this critical commercial initiative. We believe our solutions and services will accelerate LEO's commercial effectiveness as their business continues to grow across the globe," said Dan Goldsmith, general manager for Veeva Europe.

"Implementing Veeva CRM will also ensure tailored interactions with our unique customers in these new markets. And with Veeva's launch of iRep we see a real opportunity to integrate our CRM and CLM solutions on the iPad to increase the efficiency, effectiveness, and connectivity of our field force in the future," concluded Rene Jorgensen.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Georgetown study raises concerns over aspirin's role in breast cancer treatment